Clinical trials: Motor Neurone Disease
Obstructive Sleep Apnea, Amyotrophic Lateral Sclerosis
Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx
This is a pilot study to examine the diagnostic utility of a novel transmembrane surface sensor, and compare signals obtained with the transmembrane sensor to conventional needle EMG signals from healthy volunteers to those with…
- Conditions
- Obstructive Sleep Apnea, Amyotrophic Lateral Sclerosis, Muscular Dystrophies, Healthy
- Trial name
- NCT03986671
- Testing
- Transmembrane EMG Oropharynx Probe
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Powell Mansfield Inc.
Muscular Atrophy, Spinal
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
The primary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children's Hospital…
- Trial name
- DEVOTE (NCT04089566)
- Testing
- Nusinersen
- Where
- 45 sites in United States, Brazil and 16 more
- Volunteers
- 145 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
HEALEY ALS Platform Trial - Regimen C CNM-Au8
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Trial name
- NCT04414345
- Testing
- CNM-Au8
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Merit E. Cudkowicz, MD
Spinal and Bulbar Muscular Atrophy, Kennedy's Disease
A Study of NIDO-361 in Patients With SBMA
The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).
- Trial name
- PIONEER KD (NCT06411912)
- Testing
- NIDO-361
- Where
- 5 sites in Denmark, Italy and 2 more
- Volunteers
- 54 people
- Sponsor
- Nido Biosciences, Inc.
Amyotrophic Lateral Sclerosis, ALS
Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow-derived stem cells("HYNR-CS inj"), through intrathecal delivery for the treatment in patients with ALS. This study consists of 2 steps.
- Trial name
- NCT01363401
- Testing
- HYNR-CS inj, Control group
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Corestemchemon, Inc.
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.
- Trial name
- COURAGE-ALS (NCT04944784)
- Testing
- Reldesemtiv
- Where
- 84 sites in United States, Australia and 14 more
- Volunteers
- 489 people
- Sponsor
- Cytokinetics
ALS (Amyotrophic Lateral Sclerosis)
ALS Reversals - Lunasin Regimen
This is a 12-month, widely inclusive, largely virtual, single-center, open-label pilot trial utilizing a historical control group.
- Trial name
- NCT02709330
- Testing
- Lunasin Regimen, Historical control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Richard Bedlack, M.D., Ph.D.
Amyotrophic Lateral Sclerosis
A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis
People with Amyotrophic Lateral Sclerosis (ALS) will use a P300 based brain computer interface (BCI) keyboard to type in assistive technology devices.
- Trial name
- NCT01119001
- Testing
- P300 Brain Computer Interface Keyboard
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Michigan
Amyotrophic Lateral Sclerosis
Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)
About 213 people with ALS will participate in this study. There will be locations in North and South America. During the first part, participants will be randomly assigned to a group (like by flipping a coin).
- Trial name
- NCT03068754
- Testing
- Acthar
- Where
- 69 sites in United States, Argentina and 5 more
- Volunteers
- 143 people
- Sponsor
- Mallinckrodt
Amyotrophic Lateral Sclerosis
DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS
A disease called Amyotrophic lateral sclerosis (or ALS), which leads to difficulty swallowing, breathing, and movement, has been found to be higher for those serving in the military than in the general population.
- Trial name
- NCT02675075
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- VA Office of Research and Development
Amyotrophic Lateral Sclerosis
A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
- Trial name
- NCT05039099
- Testing
- AP-101
- Where
- 13 sites in United States, Belgium and 4 more
- Volunteers
- 73 people
- Sponsor
- AL-S Pharma
Muscular Dystrophy, Arthrogryposis
WREX Outcome Study
This study is to evaluate how the Wilmington Robotic Exoskeleton (WREX) is working for children who are using the WREX, or have used it in the past.
- Conditions
- Muscular Dystrophy, Arthrogryposis, Spinal Muscular Atrophy
- Trial name
- NCT02218593
- Testing
- WREX orthosis
- Volunteers
- 25 people
- Sponsor
- Nemours Children's Clinic
ALS
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
The purpose of this study is to evaluate the safety of oral edaravone at a dose of 105 mg administered once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period.
- Trial name
- NCT05568615
- Testing
- MT-1186
- Where
- 11 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis
This 8-week randomized, open-label evaluation will examine the acute safety and tolerability of 4 different dosing regimens of Acthar to inform dose selection for future studies of Acthar in patients with Amyotrophic Lateral…
- Trial name
- NCT01906658
- Testing
- Repository corticotropin injection
- Where
- 17 sites in United States
- Volunteers
- 43 people
- Sponsor
- Mallinckrodt
Amyotrophic Lateral Sclerosis, Alzheimer Disease
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), or asymptomatic carriers…
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NADALS (NCT05189106)
- Testing
- Baricitinib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis (ALS)
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the tolerability of L-Serine oral doses for ALS patients and assess preliminary indications of efficacy
- Trial name
- ALS (NCT03580616)
- Testing
- L-Serine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Elijah W. Stommel
Amyotrophic Lateral Sclerosis
Phase 3 Study of Dexpramipexole in ALS
The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- EMPOWER (NCT01281189)
- Testing
- Dexpramipexole
- Where
- 82 sites in United States, Australia and 9 more
- Volunteers
- 942 people
- Sponsor
- Knopp Biosciences
Muscular Atrophy, Spinal
Progressive Strength Training in Spinal Muscular Atrophy
The proposed feasibility study is necessary to test if children and young adults will participate in and adhere to a 12-week, home-based, supervised progressive strength training exercise program and to obtain preliminary data…
- Trial name
- NCT01233817
- Testing
- Progressive strength training
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Amyotrophic Lateral Sclerosis
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS.
- Trial name
- NCT00326625
- Testing
- 40 mg glatiramer acetate
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 366 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.